---
title: "Amgen Boasts Success In Sjogren's; Shares Charge Ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299788700.md"
description: "On Tuesday, Amgen's stock showed upward movement above its 50-day line following the release of positive results for its experimental treatment for Sjogren's syndrome. The company's success in this treatment contributed to its stock rising, with shares showing progress. The news highlights Amgen's promising developments in the medical field."
datetime: "2026-09-22T15:04:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299788700.md)
  - [en](https://longbridge.com/en/news/299788700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299788700.md)
generator: "portal-rs"
---

# Amgen Boasts Success In Sjogren's; Shares Charge Ahead

On Tuesday, Amgen's stock showed upward movement above its 50-day line following the release of positive results for its experimental treatment for Sjogren's syndrome. The company's success in this treatment contributed to its stock rising, with shares showing progress. The news highlights Amgen's promising developments in the medical field.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md)
- [Amgen reports a Phase 3 win with Sjögren’s drug candidate](https://longbridge.com/en/news/300046755.md)
- [Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data](https://longbridge.com/en/news/299801248.md)
- [Amgen Announces Positive Topline Phase 3 Results For Dazodalibep In Sjogren's Disease](https://longbridge.com/en/news/299775087.md)
- [Amgen's autoimmune drug succeeds in late-stage trial](https://longbridge.com/en/news/299770733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**